Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trialJoaquı́n Mateo, Johann S. de Bono, Pasquale Rescigno et al.|The Lancet Oncology|2019Cited by 643
Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate CancerAlec Paschalis, Johann S. de Bono, Beshara Sheehan et al.|European Urology|2019Cited by 464
Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancerDaniel Nava Rodrigues, Charles G. Drake, Pasquale Rescigno et al.|Journal of Clinical Investigation|2018Cited by 209
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B TrialSuzanne Carreira, Johann S. de Bono, Núria Porta et al.|Cancer Discovery|2021Cited by 161
SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone SensitivityGunther Boysen, Johann S. de Bono, Daniel Nava Rodrigues et al.|Clinical Cancer Research|2018Cited by 140